Skip to main content
Premium Trial:

Request an Annual Quote

Don't Count Us Out Yet

Over at bbgm, Deepak Singh considers a slide that's been circulating which compares the number of approved New Molecular Entities to spending by members of PhRMA from 1970 to the early 2000s. Paul Kedrosky, who presented the slide recently, notes that "the mapping of the genome, and other such inflection points in this failure-prone industry, has done nothing to accelerate [new] drugs, while causing costs to escalate dramatically."

Singh takes him to task for the comment. "I’ve seen that argument made a lot and you can’t really deny that we haven’t had a lot of success to show for the progress we’ve made over the past decade, but I’d like to stress on that last bit, past decade. Genomics, etc are very new," he writes. "We’ve barely scratched the surface, and a real impact on drug development is still years away, especially if we are talking about NMEs."

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.